Cofetuzumab
Based on 1 Customer Validation
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer.
For research use only. We do not sell to patients.
- Purity : 99.31%
- CAS No.: 1869928-62-0
- Molecular Weight:146.7 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
PTK7/CCK4
In Vitro
Cofetuzumab (10 μg/mL; 48 h) upregulates pERK1/2 in FIMM-PDC1-PDC3, and simultaneously upregulates ROR1 expression in FIMM-PDC3 with high PTK7 expression[1].
Cofetuzumab (10 μg/mL; 48 h) downregulates the expression level of SNCG protein in Kuramochi cells and FIMM-PDC1 cells[1].
Cofetuzumab (20 μg/mL; 5 days) inhibits tumor sphere formation and induces more dispersed structures in JHOS2, Kuramochi, FIMM-PDC3 and FIMM-PDC7 cells[1].
Cofetuzumab (10 μg/mL; 24 h) exerts synergistic cytotoxicity with Prexasertib (HY-18174) and Paclitaxel (HY-B0015) in FIMM-PDC3 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Kuramochi (high-grade serous ovarian cancer cell line), FIMM-PDC1 (high-grade serous ovarian cancer patient-derived cell culture)
-
Concentration:10 μg/mL
-
Incubation Time:48 h
-
Result:Downregulated synuclein-γ (SNCG) protein levels in both cell models.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human PTK7/CCK4, Fc Tag can bind Cofetuzumab. The EC50 for this effect is 21.74 ng/mL. -
Flow Cytometry analysis of Hela cells labelling PTK7/CCK4 (red) with Cofetuzumab (anti-PTK7/CCK4) (HY-P99828). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
CAS No. 1869928-62-0
-
Accession Q13308-1
-
Synonyms PF-06523435; hu24
-
Molecular Weight 146.7 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.31%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Cofetuzumab
- 1869928-62-0
- PF-06523435
- hu24
- PF06523435
- PF 06523435
- hu24
- hu 24
- hu-24
- ADC Antibodies
- RET
- PERK
- ROR
- Protein kinase R-like endoplasmic reticulum kinase
- PKR-like endoplasmic reticulum kinase
- RAR-related orphan receptor
- SNCG
- PTK7
- ovarian cancer
- spheroid formation
- patient-derived cell cultures
- ovarian cancer cells
- pERK/pAKT
- ROR1
- Kuramochi cells
- JHOS2 cells
- Inhibitor
- inhibitor
- inhibit